AltheaDx and The Nicholas Conor Institute for Pediatric Cancer Research, announced that they have entered into collaboration to:

Develop a broad panel of diagnostic, prognostic, and treatment prediction information for pediatric cancer
Provide actionable information to attending physicians that will best guide treatment for pediatric cancer
Achieve a significant milestone towards The Nicholas Conor Institute’s mission of improving diagnosis and treatment of pediatric cancer

The collaboration will build upon AltheaDx’s existing test for diagnosis of multiple pediatric tumor types, and expand the test beyond diagnosis to include prognosis and response to therapy, as well as additional cancer types. The goal of the collaboration is to produce a single genetic panel from a single biopsy that will diagnose and inform treatment.

The Nicholas Conor Institute and AltheaDx are currently seeking additional funding to cover the development costs of the program.

"We are looking forward to our collaboration with The Nicholas Conor Institute and the opportunity to provide a uniform approach to pediatric cancer diagnosis and treatment through a single, definitive test," said Dr. Joe Monforte, Chief Scientific Officer of AltheaDx. "The genetic analysis methods in our toolset can definitely make this possible."

"Our goal is to work closely with the industry to accelerate commercialization of new pediatric diagnostic tests and treatment regimens, despite the small market size, to produce better outcomes for children. Our collaboration with AltheaDx is a key part of achieving that goal," said Dr. Beth Anne Baber, co-founder and CEO of The Nicholas Conor Institute.

Source: AltheaDx